Plasma Fractionation companies

  • Report ID: 4548
  • Published Date: Aug 25, 2026
  • Report Format: PDF, PPT

Key Plasma Fractionation Market Players:

    Here is a list of key players operating in the global market:

    • CSL Behring (Australia)
    • Takeda Pharmaceutical Company (Japan)
    • Grifols (Spain)
    • Octapharma (Switzerland)
    • Kedrion Biopharma (Italy)
    • Biotest (Germany)
    • ADMA Biologics (U.S.)
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis

    The global plasma fractionation market is relatively consolidated, and it hosts a small group of large manufacturers holding broad geographic coverage and extensive portfolios, i.e., immunoglobulins, albumin, coagulation factors, and other plasma-derived therapies. CSL Behring, Takeda, Grifols, and Octapharma are among the leading global participants, which are effectively supported by integrated plasma collection, fractionation, purification, and finished-product manufacturing capabilities. Competition in this sector is structured around plasma availability, manufacturing capacity, and product innovation. In this context, Takeda in June 2024 announced an investment of USD 230 million to expand plasma fractionation capacity at its Los Angeles manufacturing site, thereby adding up to 2 million liters of annual capacity.

    Corporate Landscape of the Market:

    • CSL Behring is a leading manufacturer of plasma-derived therapies that uses plasma fractionation as a core technology. The company’s integrated operations are structured around plasma collection, fractionation, purification, and finished-product manufacturing.
    • Grifols is a central player in this sector and is a major plasma-derived medicines manufacturer with extensive fractionation and purification capabilities. Its portfolio includes immunoglobulins, albumin, and coagulation therapies.
    • Octapharma manufactures plasma-derived and recombinant therapeutic proteins, with key products being immunoglobulins, albumin, and coagulation therapies. The firm’s integrated production process covers plasma fractionation, purification, virus safety, filling, and quality control.
    • Takeda Pharmaceutical Company is yet another major manufacturer of plasma-derived therapies, which consists of an integrated business spanning plasma collection, fractionation, purification, and finished-product manufacturing.
    • Kedrion Biopharma specializes in terms of plasma-derived therapeutic products, i.e., immunoglobulins, albumin, and coagulation factors. In addition, the company’s integrated manufacturing network and research into underutilized plasma fractions support its strong position in the global market.

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In 2025, the plasma fractionation market was valued at USD 40.6 billion.

The plasma fractionation market is projected to reach USD 101.5 billion by the end of 2035, expanding at a CAGR of 9.6% over the forecast period (2026-2035).

The major players in the market are CSL Behring (Australia) ,Takeda Pharmaceutical Company (Japan) ,Grifols (Spain) ,Octapharma (Switzerland) ,Kedrion Biopharma (Italy) ,Biotest (Germany) ,ADMA Biologics (U.S.), and others.

In the product segment, the immunoglobulins sub-segment is anticipated to capture the largest market share of 61.3% in the future and exhibit lucrative growth opportunities during 2026-2035.

North America is projected to hold the largest market share of 55.4% by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos